Physician profile
Angela Stuff
NPI 1700319605
$21,775.12
in general payments reported to CMS, 2019-2025
16 companies · $895 in 2025
The $895 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,077 · 2023: $11K · 2024: $9,016 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $3,610 · Travel and Lodging: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,425.00 |
| Food and Beverage | $3,609.59 |
| Travel and Lodging | $663.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,181.15 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $840.83 | 2022-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $599.57 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $491.66 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $371.36 | 2024-2025 | Auvelity |
| Alkermes, INC. | $308.05 | 2022-2023 | Vivitrol |
| Corium, LLC | $286.44 | 2022-2023 | Azstarys |
| Neurocrine Biosciences, INC. | $125.06 | 2023 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $120.81 | 2023 | Uzedy |
| Vanda Pharmaceuticals INC. | $108.36 | 2024 | Fanapt |
| Braeburn INC. | $105.79 | 2025 | Brixadi |
| Indivior INC. | $46.03 | 2023 | Sublocade |
| Lilly USA, LLC | $33.23 | 2025 | Mounjaro |
| Alfasigma USA, INC. | $16.30 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $15.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Stuff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.